Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_assertion type Assertion NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_head.
- NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_assertion description "[Examination of the specificity of these T cells indicated that 16% of HLA-A1 TIL, 57% of HLA-A2 TIL, 7% of HLA-A3 TIL, 13% of HLA-A24 TIL, and 27% of HLA-A31 TIL recognized shared melanoma antigens restricted by major histocompatibility complex class I. Melanosomal proteins were frequently recognized by these TIL, and MART-1(27-35), gp100(154-162), gp100(209-217), and gp100(280-288) represent highly immunogenic epitopes that were recognized by a high percentage of HLA-A2 restricted melanoma reactive TIL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_provenance.
- NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_assertion evidence source_evidence_literature NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_provenance.
- NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_assertion SIO_000772 10687134 NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_provenance.
- NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_assertion wasDerivedFrom befree-2016 NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_provenance.
- NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_assertion wasGeneratedBy ECO_0000203 NP275956.RA0wQrw8e-u7zx2PH6qM0_CbKCdkSX8__aFHLgv-Dd5eM130_provenance.